Blockade of chemokine signaling in patients with multiple sclerosis

F Zipp, H Hartung, J Hillert, S Schimrigk, C Trebst, M Stangel, C Infante-Duarte, P Jakobs, C Wolf, R Sandbrink, C Pohl, M Filippi, (2006) Blockade of chemokine signaling in patients with multiple sclerosis Neurology (IF: 8.5) 67(10) 1880-3

Abstract

We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.

Links

http://www.ncbi.nlm.nih.gov/pubmed/17130431
http://dx.doi.org/10.1212/01.wnl.0000244420.68037.86

Similar articles

Tools

Export to RIS